Try GOLD - Free
Two to six, where is the fix?
Chronicle Pharmabiz
|July 24, 2025
THERE is a debate going on in the circle of highly qualified pharmacists, especially among the pharmacy teachers, that, what should be the minimum duration of pharmacist course. This is intensified after the Pharmacy Council of India announced its decision of splitting B. Pharm course into B. Pharm Industrial and B. Pharm Clinical courses. But there are lot of voices for and few against the proposal. Some even suggesting entirely a new course. Let us discuss the pros and cons of all those views in brief.
Two years pharmacist course
The people for it are conservatives or self-centered who do not want to disturb existing [for more than half a Century!] 2 years D. Pharm course. They are obviously not for the upgradation of the profession, as it may affect their business and profit! Resisting all move to upgrade the course with all their might and influence for decades, these people want to maintain status co. Now knowingly or unknowingly National Education Policy [NEP] also promotes their interest and PCI has announced it is for continuation of D. Pharm course and those who leave the B. Pharm course abruptly in the middle [after 2 years of course!] will be given Diploma in Pharmacy as per NEP. Is it not a super idea? Will they give similar diploma for the students who leave after second year MBBS? When there can be semi-baked pharmacists, why not half cooked doctors? They will make an excellent pair married to serve and save humanity! PCI which has announced earlier, its intension to abolish D. Pharm is now back tracking, simply to please their masters in the government by showing they have faithfully implemented NEP. It is more important than upgrading the profession, you know! It may be apt to quote here a para from my earlier article “Boot is on the other leg, come forward PCI” published in Pharmabiz dated 9.12.2020. “If a country is progressing means, it should upgrade its professional services by a diploma to degree to post graduate to doctoral to post-doctoral professional. Instead, we will retain all these level professional means where is the logic? Look at the developed countries, in pharmacy profession, they have moved from one year diploma to 6 years Pharm. D or M. Pharm [and stopping all short-term courses]. That is progress! Just to justify its action of prolonging D. Pharm, PCI is hiding behind NEP, we believe.” Remember it was written almost 5 years back!
Three years course
This story is from the July 24, 2025 edition of Chronicle Pharmabiz.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 10,000+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM Chronicle Pharmabiz
Chronicle Pharmabiz
US FDA fortifies alliance with Telangana DCA
A high-level delegation from the US FDA concluded a significant meeting with the DCA in Telangana, two days ago, at the DCA office in Hyderabad.
2 mins
December 11, 2025
Chronicle Pharmabiz
India exploring possibilities to expand WHO standards for Indian medicines
INDIA is looking at possibilities to expand the World Health Organisation (WHO) global benchmarking standards for medicines, in order to unify and strengthen the drug regulatory mechanism for safety, quality and efficacy of medicines sold in the country.
1 min
December 11, 2025
Chronicle Pharmabiz
Eli Lilly gets US FDA approval for Jaypirca
Eli Lilly and Company announced that the US Food and Drug Administration (FDA) has granted approval to Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets) for the treatment of adults with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma (CLL/SLL) who have previously been treated with a covalent Bruton tyrosine kinase (BTK) inhibitor.
1 mins
December 11, 2025
Chronicle Pharmabiz
Haryana DCA focuses on quality overhaul
THE Haryana drug control administration (DCA) is undertaking a major organizational overhaul focused on quality system upgrades and regulatory capacity building, particularly in response to the revised Schedule M norms.
2 mins
December 11, 2025
Chronicle Pharmabiz
DoC seeks inputs on trade issues faced with Japan
THE Department of Commerce (DoC), under the Union Commerce Ministry, has sought inputs from the industry on specific issues being faced in pharma trade with Japan.
1 min
December 11, 2025
Chronicle Pharmabiz
AIOCD asks traders to strictly comply with ban on 35 FDCs
THE All India Organisation of Chemists and Druggists (AIOCD) has issued an urgent internal circular to all its state and Union territory trade bodies, demanding immediate and strict compliance with the ban on 35 fixed dose combinations (FDCs).
3 mins
December 11, 2025
Chronicle Pharmabiz
US FDA approves Bristol Myers Squibb's Breyanzi
Bristol Myers Squibb announced that the US Food and Drug Administration (FDA) has granted approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory (R/R) marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy.
2 mins
December 11, 2025
Chronicle Pharmabiz
CN Water presents AQU@Sense MB
CN Water is now combining core water-system expertise with digital assurance has launched AQU@Sense which delivers microbial test results in under 30 minutes, replacing traditional 5 to 7 days culture based methods.
1 min
December 11, 2025
Chronicle Pharmabiz
Pharma logistics sees policy push as key catalyst for growth
INDIAN pharma's logistics sector is getting major boost from emerging policy support.
2 mins
December 11, 2025
Chronicle Pharmabiz
Lack of financial aid, expertise mar MSME prospects to meet revised Sch M deadline
INDUSTRY experts have raised alarm that lack of financial assistance and guidance on technical expertise have marred pharma MSMEs’ prospects to comply with revised Schedule M guidelines of December 31, 2025.
2 mins
December 11, 2025
Listen
Translate
Change font size
